BRISTOL MYERS SQUIBB
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer
- Conditions
- Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2019-03-13
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 437
- Registration Number
- NCT03873402
- Locations
- 🇺🇸
Local Institution - 0013, Washington, District of Columbia, United States
🇺🇸Local Institution - 0053, Athens, Georgia, United States
🇺🇸Local Institution - 0066, Boston, Massachusetts, United States
A Trial of AVID200, a Transforming Growth Factor β (TGFβ) Inhibitor, in Patients Malignancies
- First Posted Date
- 2019-02-08
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 19
- Registration Number
- NCT03834662
- Locations
- 🇺🇸
START Midwest Clinic, Grand Rapids, Michigan, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇨🇦Princess Margaret Cancer Centre, Toronto, Canada
Safety and Tolerability Study of AVID200 in Pts With Diffuse Cutaneous Systemic Sclerosis
- First Posted Date
- 2019-02-05
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 9
- Registration Number
- NCT03831438
- Locations
- 🇺🇸
UCLA, Los Angeles, California, United States
🇺🇸Hospital of Special Surgery, New York, New York, United States
🇺🇸University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
A Study of Participants in Australia Who Have Non-small Cell Lung Cancer Being Treated With Nivolumab
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Other: Non-Interventional
- First Posted Date
- 2019-01-15
- Last Posted Date
- 2022-05-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 503
- Registration Number
- NCT03804554
- Locations
- 🇦🇺
Local Institution, Heidelburg, Victoria, Australia
A Study of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid Tumors
- First Posted Date
- 2019-01-03
- Last Posted Date
- 2022-02-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 12
- Registration Number
- NCT03792750
- Locations
- 🇨🇳
Local Institution, Hangzhou, Zhejiang, China
A Study of Patients Receiving Adjuvant Nivolumab Therapy for Melanoma That Has Been Removed
- Conditions
- Melanoma
- First Posted Date
- 2018-12-11
- Last Posted Date
- 2021-09-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 152
- Registration Number
- NCT03771859
- Locations
- 🇱🇺
Local Institution, Luxembourg, Luxembourg
An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease
- Conditions
- Circulating Tumor DNANon-Small Cell Lung CancerNon-Small-Cell Lung Carcinoma
- Interventions
- Biological: NivolumabOther: Observation
- First Posted Date
- 2018-12-10
- Last Posted Date
- 2022-03-24
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT03770299
A Study of Juvenile Idiopathic Arthritis Patients Given Abatacept and the Number of Infections or Malignancies That Occur
- Conditions
- Juvenile Idiopathic Arthritis
- Interventions
- Other: Non-Interventional
- First Posted Date
- 2018-12-07
- Last Posted Date
- 2020-03-20
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 264
- Registration Number
- NCT03769558
- Locations
- 🇺🇸
Local Institution, Princeton, New Jersey, United States
A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel
- Conditions
- Acute Ischemic StrokeTransient Ischemic Attack (TIA)
- Interventions
- First Posted Date
- 2018-12-06
- Last Posted Date
- 2023-06-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 2366
- Registration Number
- NCT03766581
- Locations
- 🇺🇸
Temple University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸Local Institution - 0019, York, Pennsylvania, United States
🇺🇸Neurology Consultants of Dallas, PA, Dallas, Texas, United States
Evaluation of Safety and Effectiveness on Oral Anticoagulants
- Conditions
- Atrial Fibrillation
- Interventions
- Other: Non-Interventional
- First Posted Date
- 2018-12-05
- Last Posted Date
- 2022-05-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 12354
- Registration Number
- NCT03765242
- Locations
- 🇯🇵
Local Institution, Minato-ku, Tokyo, Japan